Dr. Kristin Waters, a clinical pharmacist in psychiatry and assistant clinical professor at the UConn School of Pharmacy will join us to examine current pharmacotherapy for Depression and Anxiety Disorders and Alcohol Use Disorder and Opioid Use Disorder. In the first half of the webinar, Dr. Waters will examine treatment for major depression and anxiety disorders which are among the most common psychiatric conditions affecting adults in the US. She will discuss the medications most commonly used in the management of major depressive disorder and anxiety disorders such as generalized anxiety disorder. While pharmacologic management may not be appropriate for all patients, it is important for social workers to have a basic understanding of these common medications. The second hour of the webinar will focus on Alcohol Use Disorder and Opioid Use Disorder. Substance use disorders (SUDs) can have a major impact on the individual, their family, and the community. Alcohol use disorder (AUD) is the most common SUD in the United States, affecting approximately 30 million people. While opioid use disorder (OUD) is less common, the mortality rate is significant due to the risk of overdose and/or unsafe behaviors associated with use that can lead to further medical complications. Most people with SUDs do not seek treatment. However, medications used in the management of AUD and OUD can improve outcomes. These medications will be discussed during this webinar.

Dr. Kristin Waters, a clinical pharmacist in psychiatry and assistant clinical professor at the UConn School of Pharmacy will join us to examine current pharmacotherapy for Depression and Anxiety Disorders and Alcohol Use Disorder and Opioid Use Disorder. In the first half of the webinar, Dr. Waters will examine treatment for major depression and anxiety disorders which are among the most common psychiatric conditions affecting adults in the US. She will discuss the medications most commonly used in the management of major depressive disorder and anxiety disorders such as generalized anxiety disorder. While pharmacologic management may not be appropriate for all patients, it is important for social workers to have a basic understanding of these common medications. The second hour of the webinar will focus on Alcohol Use Disorder and Opioid Use Disorder. Substance use disorders (SUDs) can have a major impact on the individual, their family, and the community. Alcohol use disorder (AUD) is the most common SUD in the United States, affecting approximately 30 million people. While opioid use disorder (OUD) is less common, the mortality rate is significant due to the risk of overdose and/or unsafe behaviors associated with use that can lead to further medical complications. Most people with SUDs do not seek treatment. However, medications used in the management of AUD and OUD can improve outcomes. These medications will be discussed during this webinar. Learning Objectives: • Identify medications that are considered first-line therapy for the management of major depressive disorder and the anxiety disorders discussed • Describe the basic mechanism of action of antidepressant medications and other medications commonly used to manage anxiety • Describe the most common side effects associated medications discussed including the black box warning for increased suicidal thoughts and behaviors for patients less than 25 years old • Identify medications that are considered first-line therapy for the management of alcohol use disorder and opioid use disorders • Describe logistical considerations surrounding how patients obtain medications used for OUD • Discuss risks and benefits of pharmacologic strategies and role of medications in harm reduction

The Lowell P. Weicker, Jr. Clinical Research Center (CRC) Seminar Series On Methods in Clinical Research Provided by University of Connecticut School of Medicine, Office of Community and Continuing Medical Education, and the Clinical Research Center "Do Environmental Toxins Cause Parkinson's Disease? Evidence from and Limitations of Epidemiologic Studies" Joy Antonelle de Marcaida, M.D. Medical Director Hartford HealthCare Chase Family Movement Disorders Center Hartford HealthCare Neuroscience Institute Associate Clinical Professor of Neurology UConn School of Medicine Date: June 17, 2025 Time: 12:00 Noon – 1:00 PM Location: Low Learning Center, UConn Health WebEx: https://uchc.webex.com/meet/Low; Meeting Number: 802 441 280 Join by phone: +1-415-655-0003 US Toll; Access code: 802 441 280 A light lunch and beverage will be provided. Target Audience: Faculty, staff, residents, and students interested in clinical research. Learning Objectives: Participants will (be able to): 1) Identify environmental toxins that can cause Parkinson's Disease; 2) Assess the strength of epidemiologic data on this topic; 3) Encourage advocacy for further research and better regulation against environmental toxins. Speaker Disclosure Statement: Dr. Joy Antonelle de Marcaida, in her role as speaker for this educational event, has no relevant financial relationship(s) with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that need to be disclosed. Dr. de Marcaida will not be discussing the off-labeled or investigational use of any product or device. Accreditation: The University of Connecticut School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Connecticut School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Conflict of Interest Policy: All faculty members participating in CME activities provided by the University of Connecticut School of Medicine are required to disclose to the program audience any actual or apparent conflict of interest related to the content of their presentations. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. Activity Director Disclosure Statement: Dr. Sheila Alessi, as the activity director, for this educational event, has no relevant financial relationship(s) with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that need to be disclosed. Planning Committee Disclosure Statement: Dr. Victor Hesselbrock, Dr. Jonathan Covault, Dr. Sheila Alessi, Dr. Rajesh Lalla, Ms. Elizabeth Laska, Ms. Sharon DiMauro, and Ms. Lisa Godin, as members of the planning committee for this educational event, have no relevant financial relationships with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that need to be disclosed. Commercial Support: This CME activity has no commercial support associated with it. Evaluations: Participants are required to complete an electronic evaluation in order to obtain CME Credits and/or Certificate for this activity. All evaluations must be completed within 10 business of receiving the email evaluation assignment. Return completed evaluations to Lisa Godin at Godin@uchc.edu.

For the full class schedule, descriptions, and to register, please visit the UConn Recreation website (https://recreation.uconn.edu/group-fitness-schedule/).

For the full class schedule, descriptions, and to register, please visit the UConn Recreation website (https://recreation.uconn.edu/group-fitness-schedule/).

For the full class schedule, descriptions, and to register, please visit the UConn Recreation website (https://recreation.uconn.edu/group-fitness-schedule/).